[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].

Abstract excerpt

Triple combination therapy with pegylated interferon, ribavirin and telaprevir is currently considered the gold standard for the treatment of chronic hepatitis C virus (HCV) infection. The most important features are an increase in rates of sustained viral response (74-79% vs 46% with pegylated interferon and ribavirin), as well as the possibility of early cessation of ineffective therapy due to the application...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anemia
• Share to Drug Eruptions
• Share to Exanthema